Preticks
.
Follow Us
TR
News Details
Tonix Pharmaceuticals Achieves 50 Percent Enrollment in Phase 3 RELIEF Study of TNX-102 SL (Cyclobenzaprine HCl Sublingual Tablets) for Management of Fibromyalgia
About Tonix Pharmaceuticals Holding Corp.
NASDAQ: $TNXP
Notified: $0.81
07:01 EDT
Price Chart